Company Overview and News

3
Prospect Capital's Detailed Dividend And NAV Sustainability Analysis - Part 1 (Includes Remaining Fiscal Year 2019 Monthly Dividend Projection)

2018-09-17 seekingalpha
Following continued requests due to recent earnings, Part 1 of this article analyzes PSEC's dividend sustainability by performing three tests based on recent (and projected) quarterly results.
ARCC MAIN GAIN GAINM GADDP PSEC NEWTZ ARU MSCA.CL SLRC MSCA TSLX NEWT NEWTL PBB SLRA MO

6
Main Street Capital's NAV, Dividend, And Valuation Compared To 14 BDC Peers (Post Q2 2018 Earnings) - Part 2

2018-09-13 seekingalpha
Part 2 of this article compares MAIN’s recent dividend per share rates, yield percentages, and several other dividend sustainability metrics to fourteen other BDC peers.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK MDLY NEWTL PBB

4
Prospect Capital's NAV, Valuation, And Dividend Compared To 14 BDC Peers (Post Q2 2018 Earnings)

2018-09-10 seekingalpha
Following multiple requests, this “supplemental” article compares PSEC’s recent quarterly change in NAV, quarterly and trailing twelve-month economic return, NII, and current valuation to 14 BDC peers.
AIY AINV GAIN MCQ GAINM MCV PFLT OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK NEWTL PBB

 
NEWT / Newtek Business Services Corp. 497

2018-08-31 sec.gov
tv500650-497 - none - 118.6012338s TABLE OF CONTENTS
NEWT

 
NEWT / Newtek Business Services Corp. POS EX

2018-08-31 sec.gov
As filed with the Securities and Exchange Commission on August 31, 2018
NEWT

 
Bidding Adieu To A Top Pick: Newtek Business Services Corp.

2018-08-30 seekingalpha
After a near 550% climb for our clients since initiating coverage in early 2013, we are dropping coverage.
NEWT NEWTL NEWTZ

3
SBIC & Commercial Finance Industry Outlook: Prospects Look Good

2018-08-28 zacks
Rising consumer confidence, lower unemployment rate and lesser tax rates will likely drive the performance of SBIC & commercial finance stocks. These stocks mainly invest in debt and equity of small and mid-sized privately held developing companies. Steadily improving U.S. economy and robust economic data are expected to lead to rise in demand for such loans. Moreover, regulatory changes are expected to work in favor for SBIC & commercial finance stocks.
SAB REGN TCRX TCRD TCRZ NEWTZ TSLF SAR SAQ TPVZ TPVY OFS NEWT TPVG NEWTL

5
Assessing Oaktree Strategic Income's Results For Fiscal Q3 2018 (Includes Current Recommendation)

2018-08-27 seekingalpha
Due to the recent change in management, readers have asked if I could take a look at OCSI to determine whether operations have improved enough to currently justify an investment.
ACSF AIY AINV GAIN MCQ GAINM OAK MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX BLK NEWTL PBB

 
Newtek Business Services Corp. Declares Third Quarter 2018 Dividend of $0.48 per Share

2018-08-23 globenewswire
LAKE SUCCESS, N.Y., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Newtek Business Services Corp. (“Newtek”) (Nasdaq: NEWT), an internally managed business development company ("BDC"), today announced that its Board of Directors declared a third quarter 2018 cash dividend1 of $0.48 per share. The third quarter dividend is payable on September 28, 2018 to shareholders of record as of September 17, 2018. Newtek also reiterated its 2018 annual cash dividend forecast of $1.
TSCC NEWT NEWTL NEWTZ

5
Analyzing Oaktree Specialty Lending's Results For Fiscal Q3 2018 (Includes Investment Rating Analysis)

2018-08-20 seekingalpha
This article assesses OCSL’s performance for the fiscal third quarter of 2018 (calendar second quarter of 2018) and compares results over the trailing twelve months.
ACSF AIY AINV GAIN MCQ GAINM OAK MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX BLK NEWTL PBB

 
NEWT / Newtek Business Services Corp. 10-Q (Quarterly Report)

2018-08-08 sec.gov
Document UNITED STATES
NEWT

5
Analyzing Main Street Capital's Results For Q2 2018 (Includes Updated Price Target)

2018-08-07 seekingalpha
This article assesses MAIN’s performance for Q2 2018 and compares results over the trailing 12 months.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX NEWTL PBB

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to NEWT / Newtek Business Services Corp. on message board site Silicon Investor.

Did Newt Blow it for the GOP? Did Newt Blow it for the GOP? Did Newt Blow it for the GOP?
CUSIP: 652526203